News About: Pharm. Industry
Draft for the improvement measure of KPA’s electoral system by end of the year
The Korean Pharmaceutical Association’s(KPA) Special Committee to Improve the Electoral System announced “We’ll prepare improvement measures for the rational election, and propose an agenda through public hearings by ...
Multinational pharmas earning tons of money in Korea, stingy over contributions to society
It was observed multinational pharmaceutical companies, earning an enormous amount of money in the Korean market, have been stingy on spending contributions to the Korean society.
Moreover, it was observed 9 multinat...
7 of 10 multinational pharmas reduce entertainment expenses due to Kim Young Ran Law
The Kim Young Ran Law enforced last year was analyzed to reduce entertainment expenses on multinational pharmaceutical companies.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of 2016 audit reports...
Company returning innovative pharma certi. Respects MOHW’s decision, but a tad sorry
In regards to returning the innovative pharmaceutical company certificate to the Ministry of Health and Welfare(MOHW), the company A expressed a stance that the company respect the MOHW’s decision and is sorry about t...
‘Rebate-involved’ 2 pharmas lost position as innovative pharmaceutical company
The pharmaceutical companies which got involved with rebate was finally removed from the list of innovative pharmaceutical companies.
The Ministry of Health and Welfare removed the 2 companies that lost the position ...
Via Davinci and Hanlim MS recorded ‘highest’ KRW 36.4 billion dividends and 876% dividend payout ratio each
Pharmaceutical distribution companies paid the total KRW 93.3 billion dividends based on their performance of the last year. Among them, Via Davinci and Hanlim MS became the top in the amount of dividends and the divi...
Multinational pharmas’ trend to reduce advertising expenses by 7%
It was observed multinational pharmaceutical companies are reducing expenses for advertising.
It seems they have cut advertising expenses because there is no reason to increase them as most of their products are ETC ...
MSD Korea’s antibody, Zerbaxa’s approval in Korea‘Zerbaxa(generic name: ceftolozane+tazobactam),’ a MSD Korea’s(CEO Avi BenShoshan) new antibody, acquired sales approval in Korea. On the 7th, the Ministry of Food and Drug Safe...
|
What is the main reason for low profitability of multinational pharma?
It was observed the multinational pharmaceutical companies’ sales cost rate reached 70%. The ratio was higher than the one of Korean pharmaceutical companies, 60%.
It was criticized, that is, the reason why they have...
War of words between prosecution and defendant over former witness’s testimony
The prosecution and the defense counsel had a tense war of nerves over questioning the former Novartis employee, who accepted provision of rebates via specialized magazines and service companies.
The Criminal Departm...
